Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of the KEYNOTE-100 trial (NCT02674061) of pembrolizumab in advanced recurrent ovarian cancer patients. Importantly, no significant difference in response rate was found between heavily and less heavily pretreated patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).